CRP

Product Inquiry

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
BezisterimHE-3286; NE-3107Phase 3 ClinicalHarbor Therapeutics, Biovie IncDiabetes Mellitus, Type 2; Brain Injuries, Traumatic; Insulin Resistance; Arthritis, Rheumatoid; Post-Acute COVID-19 Syndrome; Alzheimer Disease; Colitis, Ulcerative; Parkinson Disease
Details
PN-235JNJ-77242113; PN-235; JNJ-2113; PN-21235; JNJ-77242113-AACPhase 3 ClinicalProtagonist Therapeutics IncPsoriasis; Colitis, Ulcerative; Plaque psoriasis
Details
PN-232PN-232; JNJ75105186Phase 1 ClinicalProtagonist Therapeutics Inc
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Ustekinumab biosimilar (Samsung Bioepis)SB-17; SB17ApprovedSamsung Bioepis Co LtdPyzchivaEUCrohn Disease; Colitis, UlcerativeSamsung Bioepis Nl Bv2024-04-19Gastrointestinal Diseases; Skin Diseases; Psoriasis; Arthritis, Psoriatic; Rheumatic Diseases; Colitis, Ulcerative; Inflammation; Crohn Disease; Plaque psoriasis
Details
  • Product Inquiry
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland